These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35485928)

  • 1. Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study.
    Zhang K; Jones CM; Compton WM; Guy GP; Evans ME; Volkow ND
    J Clin Psychiatry; 2022 Apr; 83(3):. PubMed ID: 35485928
    [No Abstract]   [Full Text] [Related]  

  • 2. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
    Morgan JR; Schackman BR; Weinstein ZM; Walley AY; Linas BP
    Drug Alcohol Depend; 2019 Jul; 200():34-39. PubMed ID: 31082666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
    Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
    Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
    J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic relationships between Veterans and buprenorphine providers and effects on treatment retention.
    Vakkalanka JP; Lund BC; Arndt S; Field W; Charlton M; Ward MM; Carnahan RM
    Health Serv Res; 2022 Apr; 57(2):392-402. PubMed ID: 34854083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
    Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
    Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome?
    O'Connor AB; O'Brien L; Alto WA; Wong J
    J Matern Fetal Neonatal Med; 2016; 29(1):112-4. PubMed ID: 25394611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis.
    Kimmel SD; Walley AY; Li Y; Linas BP; Lodi S; Bernson D; Weiss RD; Samet JH; Larochelle MR
    JAMA Netw Open; 2020 Oct; 3(10):e2016228. PubMed ID: 33052402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Discontinuation of Buprenorphine Therapy for Opioid Use Disorder Among Privately Insured Adults.
    Agbese E; Leslie DL; Manhapra A; Rosenheck R
    Psychiatr Serv; 2020 Aug; 71(8):779-788. PubMed ID: 32264801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder.
    Chang HY; Daubresse M; Saloner B; Alexander GC
    Med Care; 2019 Sep; 57(9):667-672. PubMed ID: 31404013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.